Fight Colorectal Cancer hosted an advocacy event on the National Mall March 16, “Call-on Congress,” to discuss ways to reduce colorectal cancer incidence, improve treatment, and mitigate health disparities. The event included a flag installation on the Mall to honor those affected by CRC.
Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
